Vorinostat in Patients With Class 2 High Risk Uveal Melanoma
Status:
Withdrawn
Trial end date:
2020-01-29
Target enrollment:
Participant gender:
Summary
This proof-of-concept study will evaluate the ability of vorinostat to induce the
transformation of Class 2 uveal melanoma cells into a cell phenotype that resembles normal
melanocytes.
Phase:
Early Phase 1
Details
Lead Sponsor:
Nicolas Acquavella University of Miami
Collaborator:
University of Miami Sylvester Comprehensive Cancer Center